2024 - 2024

FUROSCIX®

First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection
Filing Acceptance of Supplemental New Drug Application (sNDA) Seeking to Expand FUROSCIX Indication to Include Chronic Kidney Disease
Positive Topline Study Results for SCP-111 (Furosemide 80 mg/1 mL) Autoinjector
FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure
Financings Totaling Up to $125 Million with Perceptive Advisors